Interventions for valvular disease Sapien 3 Ultra balloon-expandable transcatheter aortic valve: in-hospital and 30-day results from the multicentre S3U registry Saia F, Gandolfo C, Palmerini T, Berti S, Doshi SN, Laine M, Marcelli C, Piva T, Ribichini F, De Benedictis M, Cardaioli F, Cannata S, Tarantini G November 26, 2019 | 10.4244/EIJ-D-19-00541
Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry Meliga E, De Benedictis M, Chieffo A, Latib A, Park S-J, Kim Y, Onuma Y, Capranzano P, Jegere S, Makkar R, Palacios I, Buszman P, Bande M, Chakravarty T, Mehran R, Naber C, Scrocca I, Margey R, Leon M, Moses J, Fajadet J, Lefèvre T, Morice M, Erglis A, Tamburino C, Alfieri O, Conte M, Serruys P, Colombo A November 29, 2013 | 10.4244/EIJV9I7A133
New issue Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue (Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right)) December 6, 2019
Trials Book Discover 5 new trials: GALILEO, CONDI-2/ERIC-PCI, EVOLUTE II-5 years, SCOPE and Excel 5 years (The Trials book is supported by Biotronik) December 13, 2019
Editorial 2019 – A leap year for valvular heart disease (Course directors PCR London Valves 2019) November 15, 2019